💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

US STOCKS-Wall St rises on solid manufacturing data

Published 02/01/2011, 10:28 AM
Updated 02/01/2011, 10:32 AM

* UPS, Pfizer climb on earnings

* ISM manufacturing tops expectations

* 200,000 rally in Cairo in anti-govt protest

* Indexes up: Dow 0.8 pct, S&P 1.1 pct, Nasdaq 1.2 pct

* For up-to-the-minute market news see [STXNEWS/US] (Adds details on ISM manufacturing data, quote, updates prices)

By Chuck Mikolajczak

NEW YORK, Feb 1 (Reuters) - U.S. stocks rose on Tuesday as solid manufacturing data in the United States and Europe helped investors turn their attention away from the turmoil in the Middle East to hopes that a global economic recovery was on track.

The U.S. manufacturing sector expanded at its fastest pace since May 2004 in January, and prices paid jumped more than expected, according to an industry report. For details, see [ID:nN01292459]

"It is a modest increase telling us that the manufacturing sector of the economy continues to improve somewhat steadily since July of 2010," said Hugh Johnson, chief investment officer of Hugh Johnson Advisors LLC in Albany, New York.

"This is on balance, good news and I defy anybody to find a problem with this."

The Dow Jones industrial average <.DJI> advanced 88.93 points, or 0.75 percent, at 11,980.86. The Standard & Poor's 500 Index <.SPX> was up 14.02 points, or 1.09 percent, at 1,300.14. The Nasdaq Composite Index <.IXIC> jumped 31.51 points, or 1.17 percent, at 2,731.59.

Investors appeared to shrug off the tumultuous events in Egypt as more than 200,000 Egyptians poured into central Cairo in the biggest demonstration so far against President Hosni Mubarak's authoritarian rule. [ID:nLDE710178] and [ID:nLDE71016A]

United Parcel Service Inc rose 3.5 percent to $74.10 after profit at the world's largest package delivery group beat estimates and it forecast record-high earnings in 2011. [ID:nN27265145]

Dow component Pfizer Inc climbed 4 percent to $18.95 after the drugmaker announced an additional $5 billion stock buyback plan, even as it cut its sales projection for 2012. [ID:nN01256914] (Reporting by Chuck Mikolajczak; editing by Jeffrey Benkoe)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.